Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis.

Blood cancer journal·2026
Same author

Induction immunochemotherapy followed by concurrent chemoradiotherapy improves survival in unresectable esophageal cancer: a systematic review, meta-analysis, and network meta-analysis.

Frontiers in immunology·2026
Same author

Physical activity and cancer survival: the role of peripheral blood immune and inflammatory markers in reducing mortality-a retrospective cohort study based on NHANES 1999-2018.

Translational cancer research·2026
Same author

Novel oral chidamide and valganciclovir regimen for EBV-PTLD post-hematopoietic stem cell transplantation: A case report.

Medicine·2026
Same author

Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial.

Journal of hematology & oncology·2026
Same author

Crosstalk between cytokines and tryptophan metabolism: Therapeutic potential for immune effector cell-associated neurotoxicity syndrome.

Biochemical pharmacology·2026

Related Experiment Video

Updated: Jul 13, 2025

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

12.7K

Targeting CD22 for B-cell hematologic malignancies.

Jia Xu1,2, Wenjing Luo1,2, Chenggong Li3,4

  • 1Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.

Experimental Hematology & Oncology
|October 11, 2023
PubMed
Summary

CD19-targeted CAR-T cell therapy is effective for B-cell cancers, but relapse occurs. CD22-targeted therapies offer a promising alternative for patients resistant to CD19 treatments.

Keywords:
CD22CD22 CAR-T cell therapyCD22 antibody–drug conjugateCombination therapiesDual-targeting CAR-T cell

More Related Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.8K
Generation of Human CD40-activated B cells
13:27

Generation of Human CD40-activated B cells

Published on: October 16, 2009

15.3K

Related Experiment Videos

Last Updated: Jul 13, 2025

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

12.7K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.8K
Generation of Human CD40-activated B cells
13:27

Generation of Human CD40-activated B cells

Published on: October 16, 2009

15.3K

Area of Science:

  • Immunotherapy
  • Oncology
  • Molecular Biology

Background:

  • CD19-targeted chimeric antigen receptor (CAR)-T cell therapy shows efficacy in B-cell malignancies.
  • Tumor relapse due to CD19-negative disease remains a significant challenge.
  • CD22 is expressed independently of CD19 on malignant B cells, presenting a viable alternative target.

Purpose of the Study:

  • To review the molecular and physiological characteristics of CD22.
  • To discuss the development and clinical application of CD22-targeted therapies, including antibody-drug conjugates (ADCs) and CAR-T cells.
  • To explore strategies for overcoming tumor escape and improving treatment efficacy.

Main Methods:

  • Literature review of CD22 characteristics.
  • Analysis of development pathways for CD22 ADCs and CAR-T cells.
  • Synthesis of clinical data on CD22-targeted therapies.

Main Results:

  • CD22-targeted therapies (ADCs and CAR-T cells) are in clinical use with promising efficacy and acceptable toxicities.
  • CD22 serves as a crucial target for overcoming CD19-resistant B-cell relapses.
  • Established clinical data supports the therapeutic potential of targeting CD22.

Conclusions:

  • CD22-targeted therapies represent a vital advancement for managing relapsed or refractory B-cell malignancies.
  • Further research into overcoming tumor escape mechanisms is essential for enhancing CD22-targeted therapy outcomes.
  • CD22 targeting offers a robust strategy to improve sustained remission rates in B-cell cancers.